How Testosterone and Obesity Form a Vicious Cycle in Aging Men

Obesity and testosterone deficiency are deeply intertwined conditions that disproportionately affect aging men, creating a self-reinforcing cycle that accelerates metabolic decline. As global populations age, understanding this relationship has become a pressing clinical priority. This comprehensive 2025 review synthesizes evidence on the physiological mechanisms linking low testosterone to obesity, the role of chronic inflammation, the gut microbiota connection, and the therapeutic landscape of testosterone replacement therapy (TRT).

Testosterone suppresses fat accumulation through multiple pathways: it reduces lipoprotein lipase (LPL) activity in adipocytes, upregulates beta-adrenergic receptors to promote lipolysis, activates androgen receptor (AR)-mediated pathways (including ELOVL3 regulation and Wnt signaling), and promotes physical activity via dopamine and estrogen receptor α signaling in the hypothalamus. When testosterone levels fall, these protective mechanisms are compromised, leading to visceral fat expansion. Simultaneously, testosterone is critical for skeletal muscle protein synthesis and satellite cell proliferation; its decline leads to sarcopenia, lowered basal metabolic rate, and heightened obesity risk.

Obesity-related chronic inflammation — termed 'metabolic inflammation' — creates a particularly damaging feedback loop. Hypertrophied visceral adipocytes secrete pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and ligands such as lipopolysaccharide and saturated fatty acids that activate TLR4/NF-κB signaling. This inflammatory milieu disrupts the HPG axis, suppressing gonadotropin-releasing hormone and luteinizing hormone secretion, thereby reducing testicular testosterone output. Preclinical evidence suggests testosterone itself may suppress TLR4 expression and NF-κB signaling, indicating a direct anti-inflammatory role.

An emerging area of focus is the gut–testis axis. Animal studies show that castration alters gut microbial composition — increasing the Firmicutes/Bacteroidetes ratio and Lactobacillus abundance — patterns associated with obesity. In humans, higher testosterone correlates with greater microbial diversity. Short-chain fatty acids (SCFAs) produced by gut bacteria may stimulate Leydig cell testosterone synthesis via cAMP/PKA signaling and upregulation of luteinizing hormone receptors. Specific bacterial species (e.g., Butyricicoccus desmolans, Clostridium scindens) can synthesize androgenic precursors, suggesting the gut microbiome functions as an extra-gonadal androgen source. Obesity-induced gut dysbiosis and increased intestinal permeability exacerbate systemic inflammation, further impairing testosterone production.

Regarding TRT, recent large trials (including TRAVERSE) have provided reassurance on cardiovascular safety in men with hypogonadism, though concerns about polycythemia, sleep apnea, and prostate health require monitoring. TRT benefits in obese men include reductions in fat mass, improvements in insulin sensitivity, and reduced inflammatory markers. Notably, racial differences and genetic polymorphisms in androgen receptor CAG repeat length affect testosterone bioavailability and TRT responsiveness, reinforcing the case for individualized treatment. The review calls for further research into microbiome-targeted interventions and pharmacogenomic approaches to optimize TRT outcomes.